Psoriatic arthritis (PsA) is a complex inflammatory disease linked to psoriasis, often accompanied by comorbidities that impact prognosis and quality of life. Despite new drugs with strong efficacy and favorable safety profiles, managing PsA remains challenging, as some patients do not respond well to treatment. Recent research from 2022 to mid-2024 has focused on various aspects of PsA, including pathogenesis, diagnostic imaging, therapies, and comorbidities. Imaging techniques like ultrasound and MRI are crucial for diagnosing and monitoring PsA, detecting both inflammation and damage, and evaluating treatment effectiveness. Disease activity indices such as DAPSA and PASDAS are key for tracking PsA progression.

Patients with PsA often face comorbidities like cardiovascular disease, obesity, and depression, which worsen disease burden and quality of life. Factors like BMI and disease activity influence treatment outcomes, with obesity linked to lower chances of achieving minimal disease activity. New therapies, including TNF inhibitors (TNFi), IL-17 inhibitors (IL17i), and IL-23 inhibitors (IL23i), have proven effective in managing PsA symptoms and improving quality of life. Drugs like secukinumab, ixekizumab, and bimekizumab have shown strong efficacy across PsA domains. Additionally, emerging artificial intelligence (AI) and machine learning (ML) models offer promising tools for enhancing diagnosis and personalizing treatment plans.

Reference: Esti L, Fattorini F, Cigolini C, et al. Clinical aspects of psoriatic arthritis: one year in review 2024. Clin Exp Rheumatol. 2025 Jan;43(1):4-13. doi: 10.55563/clinexprheumatol/7gug1a. Epub 2025 Jan 23. PMID: 39846367.